NervGen names Sam Jackson chief medical officer
NGEN•NervGen appointed Sam Jackson chief medical officer; he will lead its Phase 3 RESTORE study and support NVG-291's expansion into additional indications.
1. New medical officer
Jackson most recently served as chief medical officer, neuroscience, at Aditum Bio, leading clinical development across its neuroscience portfolio. At NervGen, he will lead the ongoing Phase 3 RESTORE study and support NVG-291's clinical expansion into additional indications.




